阿替利珠单抗致4级免疫检查点抑制剂相关性肺炎死亡1例
One death case report of grade Ⅳ checkpoint inhibitor pneumonitis induced by atezolizumab
徐保平 1刘凯 2王晓涛 3彭怀文1
作者信息
- 1. 安徽中医药大学第四临床医学院/六安市中医院重症医学科,安徽六安 237000
- 2. 安徽中医药大学第四临床医学院/六安市中医院放疗科,安徽六安 237000
- 3. 无锡市锡山人民医院鹅湖分院中医科,江苏无锡 214116
- 折叠
摘要
阿替利珠单抗是一种人源化单克隆抗体,随着阿替利珠单抗临床广泛使用,免疫相关不良事件报道逐渐增加.阿替利珠单抗致免疫检查点抑制剂相关性肺炎(checkpoint inhibitor pneumonitis,CIP)是一种罕见的危及生命的不良事件,国内尚无病例报告.该文报道并分析了1例使用阿替利珠单抗5个月后出现CIP的肾癌患者,以期提高临床医师对阿替利珠单抗相关不良反应的认识.
Abstract
Attillizumab is a humanized monoclonal anti-body.With its widespread clinical application,there are grow-ing reports of immune-related adverse events.Checkpoint inhibitor pneumonitis(CIP)induced by attilizumab is a rare life-threatening adverse event.It has never been reported in China.Here we described and analysis an onset of CIP in a renal cancer patient after a 5-month therapy of attilizumab to enhance clinicians'understanding of its adverse effects.
关键词
免疫检查点抑制剂相关性肺炎/免疫相关性肺炎/阿替利珠单抗/肾癌/药物不良反应Key words
checkpoint inhibitor pneumonitis/immune-associated pneumonia/atezolizumab/renal cancer/adverse drug reaction引用本文复制引用
出版年
2024
NETL
NSTL
万方数据